1
Participants
Start Date
September 27, 2023
Primary Completion Date
June 6, 2025
Study Completion Date
June 6, 2025
Atezolizumab and bevacizumab
Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle and Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle
transarterial chemoembolization (TACE) or transarterial radioembolization (TARE
TACE cycles occur every 8 weeks +/- 7 days OR TARE cycles occur every 12 weeks +/- 7 days
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas
Collaborators (1)
Genentech, Inc.
INDUSTRY
University of Texas Southwestern Medical Center
OTHER